|
TW200801012A
(en)
*
|
2006-04-26 |
2008-01-01 |
Piramed Ltd |
Phosphoinositide 3-kinase inhibitor compounds and methods of use
|
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
|
MX353308B
(es)
|
2008-05-21 |
2018-01-08 |
Ariad Pharma Inc |
Derivados fosforosos como inhibidores de cinasa.
|
|
US9556426B2
(en)
|
2009-09-16 |
2017-01-31 |
Celgene Avilomics Research, Inc. |
Protein kinase conjugates and inhibitors
|
|
US8946197B2
(en)
|
2009-11-16 |
2015-02-03 |
Chdi Foundation, Inc. |
Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof
|
|
JP2013516422A
(ja)
|
2009-12-30 |
2013-05-13 |
アビラ セラピューティクス， インコーポレイテッド |
タンパク質のリガンド−指向性共有的修飾
|
|
US9295673B2
(en)
|
2011-02-23 |
2016-03-29 |
Intellikine Llc |
Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
|
|
CA2829558A1
(en)
*
|
2011-03-09 |
2012-09-13 |
Celgene Avilomics Research, Inc. |
Pi3 kinase inhibitors and uses thereof
|
|
EP2704572B1
(en)
|
2011-05-04 |
2015-12-30 |
Ariad Pharmaceuticals, Inc. |
Compounds for inhibiting cell proliferation in egfr-driven cancers
|
|
WO2012154608A1
(en)
*
|
2011-05-06 |
2012-11-15 |
Intellikine, Llc |
Reactive mtor and pi3 kinase inhibitors and uses thereof
|
|
WO2012154610A1
(en)
*
|
2011-05-06 |
2012-11-15 |
Intellikine, Llc |
Reactive pi3k kinase inhibitors and uses thereof
|
|
US8889716B2
(en)
|
2011-05-10 |
2014-11-18 |
Chdi Foundation, Inc. |
Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof
|
|
JP2014520863A
(ja)
|
2011-07-13 |
2014-08-25 |
ファーマサイクリックス，インク． |
Ｂｒｕｔｏｎ型チロシンキナーゼの阻害剤
|
|
BR112014007310A2
(pt)
|
2011-09-27 |
2017-04-04 |
Novartis Ag |
3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
|
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
|
WO2013144180A1
(en)
*
|
2012-03-28 |
2013-10-03 |
Intervet International B.V. |
Heteroaryl compounds with cyclic bridging unit for use in the treatment helminth infection
|
|
EP2836482B1
(en)
|
2012-04-10 |
2019-12-25 |
The Regents of The University of California |
Compositions and methods for treating cancer
|
|
US9879003B2
(en)
|
2012-04-11 |
2018-01-30 |
Dana-Farber Cancer Institute, Inc. |
Host targeted inhibitors of dengue virus and other viruses
|
|
HUE051096T2
(hu)
|
2012-04-26 |
2021-03-01 |
Massachusetts Gen Hospital |
Ágensek és módszerek a sebészeti keratózis kezelésére és megelõzésére
|
|
WO2013169401A1
(en)
|
2012-05-05 |
2013-11-14 |
Ariad Pharmaceuticals, Inc. |
Compounds for inhibiting cell proliferation in egfr-driven cancers
|
|
US20150204846A1
(en)
*
|
2012-05-15 |
2015-07-23 |
New York University |
Phosphatidylinositol-3-kinase c2 beta modulators and methods of use thereof
|
|
WO2014012093A1
(en)
*
|
2012-07-13 |
2014-01-16 |
Wake Forest University Health Sciences |
Prostate cancer targeted prodrugs and methods of use thereof
|
|
WO2014022569A1
(en)
*
|
2012-08-03 |
2014-02-06 |
Principia Biopharma Inc. |
Treatment of dry eye
|
|
CA2879597C
(en)
|
2012-08-21 |
2021-01-12 |
Opko Pharmaceuticals, Llc |
Ophthalmic liposome formulations for treating posterior segment disease
|
|
US11458199B2
(en)
|
2012-08-21 |
2022-10-04 |
Opko Pharmaceuticals, Llc |
Liposome formulations
|
|
SI2892900T1
(en)
|
2012-09-10 |
2018-01-31 |
Principia Biopharma Inc. |
Pyrazolopyrimidine compounds as kinase inhibitors
|
|
WO2014063054A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
|
|
US9296733B2
(en)
|
2012-11-12 |
2016-03-29 |
Novartis Ag |
Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
|
|
JP6207100B2
(ja)
|
2012-12-21 |
2017-10-04 |
ギリアード カリストガ エルエルシー |
イソキノリノンまたはキナゾリノンホスファチジルイノシトール３−キナーゼ阻害剤
|
|
AU2013364068B2
(en)
|
2012-12-21 |
2016-10-20 |
Gilead Calistoga Llc |
Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
|
|
MX368903B
(es)
*
|
2013-02-20 |
2019-10-21 |
Kala Pharmaceuticals Inc |
Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
|
|
MX394360B
(es)
|
2013-03-14 |
2025-03-24 |
Sumitomo Pharma Oncology Inc |
Inhibidores de jak2 y alk2 y metodos para su uso.
|
|
JP6387360B2
(ja)
|
2013-03-14 |
2018-09-05 |
ノバルティス アーゲー |
変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン
|
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
|
US9745319B2
(en)
|
2013-03-15 |
2017-08-29 |
Araxes Pharma Llc |
Irreversible covalent inhibitors of the GTPase K-Ras G12C
|
|
EP2968340A4
(en)
*
|
2013-03-15 |
2016-08-10 |
Intellikine Llc |
COMBINING KINASE INHIBITORS AND USES THEREOF
|
|
CA2904393A1
(en)
*
|
2013-03-15 |
2014-09-25 |
Araxes Pharma Llc |
Covalent inhibitors of kras g12c
|
|
JP6378918B2
(ja)
*
|
2013-04-03 |
2018-08-22 |
株式会社ヤクルト本社 |
チアゾリジン誘導体又はその塩を有効成分とするＰｉｍ阻害剤
|
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
|
AR096151A1
(es)
*
|
2013-05-01 |
2015-12-09 |
Hoffmann La Roche |
Compuestos de biheteroarilo y usos de los mismos
|
|
US10508309B2
(en)
*
|
2013-05-17 |
2019-12-17 |
The General Hospital Corporation |
Methods for detecting and treating variants of seborrheic keratoses
|
|
PL3008053T3
(pl)
|
2013-06-14 |
2018-08-31 |
Gilead Calistoga Llc |
Inhibitory 3-kinazy fosfatydyloinozytolu
|
|
UY35675A
(es)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
Derivados sustituidos de quinazolin-4-ona
|
|
BR112016006978A2
(pt)
|
2013-09-30 |
2017-08-01 |
Pharmacyclics Llc |
inibidores de tirosina quinase de bruton
|
|
JO3805B1
(ar)
|
2013-10-10 |
2021-01-31 |
Araxes Pharma Llc |
مثبطات كراس جي12سي
|
|
ES2670550T3
(es)
|
2013-10-14 |
2018-05-30 |
Eisai R&D Management Co., Ltd. |
Derivados de quinolina selectivamente sustituidos
|
|
SG10202103278TA
(en)
|
2013-10-14 |
2021-04-29 |
Eisai R&D Man Co Ltd |
Selectively substituted quinoline compounds
|
|
WO2015058126A1
(en)
*
|
2013-10-18 |
2015-04-23 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of prolferative diseases
|
|
US10047084B2
(en)
|
2013-11-20 |
2018-08-14 |
Beijing Forelandpharma Co. Ltd. |
Imidazolone derivatives, pharmaceutical compositions and uses thereof
|
|
EP3076968B1
(en)
|
2013-12-02 |
2019-04-17 |
ChemoCentryx, Inc. |
Ccr6 compounds
|
|
CN112353806A
(zh)
|
2014-02-21 |
2021-02-12 |
普林斯匹亚生物制药公司 |
Btk抑制剂的盐和固体形式
|
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
JP2017528498A
(ja)
*
|
2014-09-25 |
2017-09-28 |
アラクセス ファーマ エルエルシー |
Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター
|
|
WO2016049568A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Methods and compositions for inhibition of ras
|
|
SG11201704808VA
(en)
|
2014-12-18 |
2017-07-28 |
Principia Biopharma Inc |
Treatment of pemphigus
|
|
ES2737227T3
(es)
|
2014-12-24 |
2020-01-10 |
Kither Biotech S R L |
Péptido inhibidor de gamma PI3K novedoso para el tratamiento de enfermedades del sistema respiratorio
|
|
ES2898765T3
(es)
|
2015-04-10 |
2022-03-08 |
Araxes Pharma Llc |
Compuestos de quinazolina sustituidos y métodos de uso de los mismos
|
|
US10428064B2
(en)
|
2015-04-15 |
2019-10-01 |
Araxes Pharma Llc |
Fused-tricyclic inhibitors of KRAS and methods of use thereof
|
|
WO2016172952A1
(zh)
|
2015-04-30 |
2016-11-03 |
江苏挪贝肽医药科技有限公司 |
PI4KIIIα蛋白及相关的膜蛋白复合体在治疗阿尔茨海默病中的应用
|
|
CA2986359A1
(en)
|
2015-05-20 |
2016-11-24 |
Novartis Ag |
Pharmaceutical combination of everolimus with dactolisib
|
|
WO2016210165A1
(en)
|
2015-06-24 |
2016-12-29 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
WO2017058728A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058805A1
(en)
*
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058902A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3356351A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356359B1
(en)
|
2015-09-28 |
2021-10-20 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356349A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356347A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
WO2017070256A2
(en)
|
2015-10-19 |
2017-04-27 |
Araxes Pharma Llc |
Method for screening inhibitors of ras
|
|
KR20180081596A
(ko)
|
2015-11-16 |
2018-07-16 |
아락세스 파마 엘엘씨 |
치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
|
|
US9988357B2
(en)
|
2015-12-09 |
2018-06-05 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
|
RU2617409C1
(ru)
*
|
2015-12-24 |
2017-04-25 |
Федеральное государственное бюджетное учреждение науки Институт элементоорганических соединений им. А.Н. Несмеянова Российской академии наук (ИНЭОС РАН) |
Амиды акриловой и метакриловой кислот с n-алкилпиперазино-пиперидинами и способ их получения
|
|
RU2617694C1
(ru)
*
|
2015-12-24 |
2017-04-26 |
Федеральное государственное бюджетное учреждение науки Институт элементоорганических соединений им. А.Н. Несмеянова Российской академии наук (ИНЭОС РАН) |
Амиды акриловой и метакриловой кислот с олигопиперидинами и способ их получения
|
|
GB201602527D0
(en)
*
|
2016-02-12 |
2016-03-30 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
|
WO2017172979A1
(en)
|
2016-03-30 |
2017-10-05 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
|
MX383920B
(es)
|
2016-05-26 |
2025-03-14 |
Recurium Ip Holdings Llc |
Compuestos inhibidores de egfr.
|
|
CN115054586B
(zh)
|
2016-06-29 |
2024-08-02 |
普林斯匹亚生物制药公司 |
改性的释放制剂
|
|
WO2018002958A1
(en)
|
2016-06-30 |
2018-01-04 |
Sun Pharma Advanced Research Company Limited |
Novel hydrazide containing compounds as btk inhibitors
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
TW201813963A
(zh)
|
2016-09-23 |
2018-04-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
|
TW201825465A
(zh)
|
2016-09-23 |
2018-07-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
|
TW201815787A
(zh)
|
2016-09-23 |
2018-05-01 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
|
WO2018064510A1
(en)
|
2016-09-29 |
2018-04-05 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3523289A1
(en)
|
2016-10-07 |
2019-08-14 |
Araxes Pharma LLC |
Heterocyclic compounds as inhibitors of ras and methods of use thereof
|
|
CN110114070A
(zh)
|
2016-11-23 |
2019-08-09 |
诺华公司 |
使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法
|
|
CN106755343A
(zh)
*
|
2016-12-01 |
2017-05-31 |
北京致成生物医学科技有限公司 |
胰腺癌预后诊断分子标记物
|
|
JP7327802B2
(ja)
|
2017-01-26 |
2023-08-16 |
アラクセス ファーマ エルエルシー |
縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
|
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
EP3573954A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
WO2018140513A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
|
US11136308B2
(en)
|
2017-01-26 |
2021-10-05 |
Araxes Pharma Llc |
Substituted quinazoline and quinazolinone compounds and methods of use thereof
|
|
US10858351B2
(en)
*
|
2017-04-26 |
2020-12-08 |
Alberta Research Chemicals Inc. |
Substituted tetrahydropyridine derivatives as IDO-1 inhibitors and uses thereof
|
|
CN110869357A
(zh)
|
2017-05-25 |
2020-03-06 |
亚瑞克西斯制药公司 |
化合物及其用于治疗癌症的使用方法
|
|
WO2018218069A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant kras, hras or nras
|
|
US10745385B2
(en)
|
2017-05-25 |
2020-08-18 |
Araxes Pharma Llc |
Covalent inhibitors of KRAS
|
|
US10596165B2
(en)
|
2018-02-12 |
2020-03-24 |
resTORbio, Inc. |
Combination therapies
|
|
KR20210003780A
(ko)
|
2018-04-05 |
2021-01-12 |
스미토모 다이니폰 파마 온콜로지, 인크. |
Axl 키나제 억제제 및 그의 용도
|
|
AU2019251363B2
(en)
|
2018-04-10 |
2024-03-07 |
Neuropore Therapies, Inc. |
Morpholine derivates as inhibitors of Vps34
|
|
KR102803762B1
(ko)
|
2018-04-10 |
2025-05-09 |
뉴로포레 테라피스, 인코포레이티드 |
Pi3-키나제 및 오토파지 경로의 조절인자로서의 트리-치환된 아릴 및 헤테로아릴 유도체
|
|
AU2019310590A1
(en)
|
2018-07-26 |
2021-01-14 |
Sumitomo Pharma Oncology, Inc. |
Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
|
|
MX2021000887A
(es)
*
|
2018-08-01 |
2021-03-31 |
Araxes Pharma Llc |
Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
|
|
KR102328682B1
(ko)
|
2018-08-27 |
2021-11-18 |
주식회사 대웅제약 |
신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
|
|
EP3849545A1
(en)
*
|
2018-09-10 |
2021-07-21 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods for the treatment of neurofibromatosis
|
|
EP3898626A1
(en)
|
2018-12-19 |
2021-10-27 |
Array Biopharma, Inc. |
Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
|
|
US12351571B2
(en)
|
2018-12-19 |
2025-07-08 |
Array Biopharma Inc. |
Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases
|
|
WO2021055747A1
(en)
|
2019-09-19 |
2021-03-25 |
Totus Medicines Inc. |
Therapeutic conjugates
|
|
US20210106584A1
(en)
|
2019-10-14 |
2021-04-15 |
Principia Biopharma Inc. |
Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
|
|
US12590298B2
(en)
|
2019-10-18 |
2026-03-31 |
The Regents Of The University Of California |
Ex vivo tumor angiogenesis model
|
|
KR20220087497A
(ko)
|
2019-10-18 |
2022-06-24 |
더 리전츠 오브 더 유니버시티 오브 캘리포니아 |
병원성 혈관을 표적화하기 위한 화합물 및 방법
|
|
US20210269434A1
(en)
*
|
2020-01-10 |
2021-09-02 |
Incyte Corporation |
Tricyclic compounds as inhibitors of kras
|
|
WO2021150613A1
(en)
|
2020-01-20 |
2021-07-29 |
Incyte Corporation |
Spiro compounds as inhibitors of kras
|
|
US11814390B2
(en)
|
2020-01-22 |
2023-11-14 |
Principia Biopharma Inc. |
Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1H-pyrazolo[3,4-D]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
|
|
KR20250133471A
(ko)
|
2020-02-18 |
2025-09-05 |
길리애드 사이언시즈, 인코포레이티드 |
항바이러스 화합물
|
|
TWI775313B
(zh)
|
2020-02-18 |
2022-08-21 |
美商基利科學股份有限公司 |
抗病毒化合物
|
|
TWI883391B
(zh)
|
2020-02-18 |
2025-05-11 |
美商基利科學股份有限公司 |
抗病毒化合物
|
|
US11739102B2
(en)
|
2020-05-13 |
2023-08-29 |
Incyte Corporation |
Fused pyrimidine compounds as KRAS inhibitors
|
|
EP4157281A4
(en)
*
|
2020-05-27 |
2024-11-27 |
Duke University |
COMPOSITIONS AND METHODS FOR SENSITIZING ACUTE MYELOID LEUKEMIAS TO CHEMOTHERAPY
|
|
US11999752B2
(en)
|
2020-08-28 |
2024-06-04 |
Incyte Corporation |
Vinyl imidazole compounds as inhibitors of KRAS
|
|
US11767320B2
(en)
|
2020-10-02 |
2023-09-26 |
Incyte Corporation |
Bicyclic dione compounds as inhibitors of KRAS
|
|
CN113045582B
(zh)
*
|
2021-02-05 |
2022-12-23 |
中国药科大学 |
Parp-1/pi3k双靶点抑制剂或其药学上可接受的盐及其制备方法与用途
|
|
WO2022198024A1
(en)
*
|
2021-03-18 |
2022-09-22 |
Totus Medicines Inc. |
Therapeutic conjugates
|
|
WO2022204112A1
(en)
|
2021-03-22 |
2022-09-29 |
Incyte Corporation |
Imidazole and triazole kras inhibitors
|
|
CN117396470A
(zh)
*
|
2021-04-09 |
2024-01-12 |
巴塞尔大学 |
作为pi3k的可逆和不可逆共价抑制剂的三嗪衍生物
|
|
KR20240008312A
(ko)
*
|
2021-04-09 |
2024-01-18 |
유니버시타트 바셀 |
Pi3k의 가역적 및 비가역적 공유 억제제로서의 트리아진 유도체
|
|
CA3216162A1
(en)
|
2021-04-16 |
2022-10-20 |
Gilead Sciences, Inc. |
Methods of preparing carbanucleosides using amides
|
|
MX2024000357A
(es)
|
2021-07-07 |
2024-02-12 |
Incyte Corp |
Compuestos triciclicos como inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras).
|
|
WO2023287896A1
(en)
|
2021-07-14 |
2023-01-19 |
Incyte Corporation |
Tricyclic compounds as inhibitors of kras
|
|
TW202321191A
(zh)
*
|
2021-07-29 |
2023-06-01 |
美商賽迪拉治療股份有限公司 |
Ｔｅａｄ抑制劑及其用途
|
|
AU2022328698B2
(en)
|
2021-08-18 |
2025-02-20 |
Gilead Sciences, Inc. |
Phospholipid compounds and methods of making and using the same
|
|
US12441742B2
(en)
|
2021-08-31 |
2025-10-14 |
Incyte Corporation |
Naphthyridine compounds as inhibitors of KRAS
|
|
WO2023049697A1
(en)
|
2021-09-21 |
2023-03-30 |
Incyte Corporation |
Hetero-tricyclic compounds as inhibitors of kras
|
|
CN113754680B
(zh)
*
|
2021-09-28 |
2022-07-22 |
云白药征武科技(上海)有限公司 |
一种α氟代酰基哌嗪衍生物及其制备和应用
|
|
CA3234375A1
(en)
|
2021-10-01 |
2023-04-06 |
Incyte Corporation |
Pyrazoloquinoline kras inhibitors
|
|
CA3235146A1
(en)
|
2021-10-14 |
2023-04-20 |
Incyte Corporation |
Quinoline compounds as inhibitors of kras
|
|
KR102939621B1
(ko)
*
|
2022-07-21 |
2026-03-17 |
주식회사 바오밥에이바이오 |
헤테로비시클릭 화합물 및 그를 포함하는 약제학적 조성물
|
|
WO2024182447A1
(en)
*
|
2023-02-28 |
2024-09-06 |
Vividion Therapeutics, Inc. |
Compounds and methods for modulating ras-pi3k
|
|
WO2025188658A1
(en)
*
|
2024-03-06 |
2025-09-12 |
Alterome Therapeutics, Inc. |
Akt1 modulators
|